Technology

Inflamalps combines:

1. A novel biological assay to detect inhibitors of multimeric cytokine receptors developed in collaboration with the University of Lausanne and the École Polytechnique Fédérale de Lausanne. It was first successfully applied to TNFR1 and is being developed for additional receptors in the TNF family.

2. Exclusive rights to screen libraries of extracts primarily from natural sources (venoms, extremophiles & plants) not yet exploited by the pharmaceutical industry to identify preferentially novel peptides and macrocycles
Peptide venoms offer a huge and yet untapped opportunity of discovering new peptide therapeutics (King GF, Expert Opin. Biol. Ther. 2011, 11, 1469-1484). Peptides from venoms are non-immunogenic, often protease-resistant due to their disulfide-rich architectures and display an extremely high specificity and potency for a large variety of molecular targets. Venom peptides may be even suitable for oral administration. Through advances in chemical synthesis or bioengineering, venoms peptides are currently relatively easy to synthesize and amenable to modification for optimization of their activity and specificity. Finally their cost-of-goods is considerably lower than biologics and consequently the cost of treatment using these new peptides would be reduced as compared with anti-TNF biologicals. Venom peptides represent an innovative opportunity for the search of compounds inhibiting the interactions between large ligands such as TNF and their receptors. Inflamalps has established an exclusive partnership with Atheris Laboratories to exploit their unique libraries and expertise in venoms derived peptides for discovering novel TNF receptor inhibitors.
Extremophile organisms have also developed unique defenses against their environment, leading to the biosynthesis of novel molecules including peptides and macrocycles (Wilson, Z.E. et al. Nat. Prod. Rep. 2009, 26, 44-71). Despite nearly 150 years in the public domain, this rich source of novel molecules remains largely unexplored. While research on extremophiles derived compounds macrocycles and peptides is still in its infancy it holds the potential of providing a wide variety of yet unexplored compounds as potential therapeutic agents. Inflamalps has established an exclusive partnership with GNS Science to discover novel peptides and macrocycle to inhibit TNF receptors. GNS Science has a growing collection of 1500 novel and unique extremophilic isolates from New Zealand’s unique geothermal and hydrothermal environments and other extreme environments.